Nowadays, there's lots of buzz about spectacular new medical treatments such as personalised cancer therapy with modified immune cells or antibodies. Such treatments, however, are very complex and ...

CHENGDU, China, July 16, 2024 /PRNewswire/ -- "Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery" webinar will be jointly hosted by HitGen Inc. and Xtalks on ...

DNA-encoded chemical libraries (DELs) have emerged as a transformative technology in drug discovery, offering unparalleled efficiency in the identification of bioactive small molecules. By covalently ...

CHENGDU, China--(BUSINESS WIRE)--HitGen and Fierce Biotech jointly release the Whitepaper: Advancing Drug Discovery through DNA-Encoded Library (DEL) Technology today. This whitepaper will provide the ...

Over the past two decades, large genetic studies have linked tens of thousands of DNA variants to thousands of human traits and diseases. Yet, correcting the effects of those variants to treat disease ...

DNA-encoded library (DEL) technology is a promising new tool for identifying ligands for challenging protein targets, allowing for the preparation and screening of large chemical libraries with ...

MADISON, Wis.--(BUSINESS WIRE)--A new study demonstrates how the combination of DNA-encoded libraries (DELs) and NanoBRET Target Engagement technology can accelerate early-stage drug discovery.

X-Chem’s DNA-encoded library complements Charles River’s discovery expertise to accelerate hit identification Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic ...

Straits Research released its highly anticipated report,“ Global DNA-encoded Library Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 851.06 million in 2025 ...

Siena (Italy), November 7 th 2022 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ...

Baylor College of Medicine and Site Tx, Inc. are collaborating to develop novel small-molecule drugs that allow for the fine-tuning of immune responses in multiple disease. Focusing on small molecule ...